Serological markers in psoriatic arthritis: promising tools

被引:23
作者
Ramonda, Roberta [1 ]
Modesti, Valentina [1 ]
Ortolan, Augusta [1 ]
Scanu, Anna [1 ]
Bassi, Nicola [1 ]
Oliviero, Francesca [1 ]
Punzi, Leonardo [1 ]
机构
[1] Univ Padua, Dept Med DIMED, Rheumatol Unit, I-35128 Padua, Italy
关键词
Psoriatic arthritis; biological markers; inflammation; tumor necrosis factor-alpha; vascular endothelial growth factor; metalloproteinase-3; ENDOTHELIAL GROWTH-FACTOR; ANTITUMOR NECROSIS FACTOR; C-REACTIVE PROTEIN; LONG PENTRAXIN PTX3; RHEUMATOID-ARTHRITIS; MATRIX METALLOPROTEINASE-3; FUNCTIONAL ASSESSMENT; DISEASE-ACTIVITY; SERUM LEVELS; SPONDYLOARTHRITIS;
D O I
10.1177/1535370213506435
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The aim of this study was to identify specific biomarkers that could be used to screen for psoriatic arthritis (PsA), as well as to assess disease activity and treatment outcome in affected patients. Forty-three outpatients considered eligible for anti-TNF-alpha treatment (etanercept 50 mg/week) were enrolled. Serum samples of vascular endothelial growth factor (VEGF), metalloproteinase-3 (MMP3), pentraxin 3 (PTX3), and high-sensitive C-reactive protein (hs-CRP) were collected at baseline (t0) and after 6 (t6), 12 (t12), and 24 months (t24) of treatment. Baseline values were compared with those of a group of healthy controls matched for age and sex. Disease activity scores and functional tests (DAS28, BASDAI, PASI, BASFI, HAQ, VAS pain, and VAS patient global disease activity) after treatment were found to be significantly different from baseline values. At baseline, MMP3, hs-CRP and VEGF values in the PsA-patients were found to be significantly higher with respect to levels in the controls. There were no differences in the PTX3 values. MMP3 was significantly lower at t6 (P < 0.0001), t12 (P < 0.0001) and t24 (P < 0.0001). hs-CRP and VEGF were significantly lower, respectively, at t12 (P < 0.01; P < 0.05) and t24 (P < 0.05; P < 0.01). PTX3 was significantly higher at t24 (P < 0.05). A correlation was found between MMP3 and hs-CRP (r = 0.45, P = 0.0005). MMP3, hs-CRP, and VEGF appear to be useful for the early detection of PsA and to monitor disease progression. The rise in PTX3 did not appear to be linked to the inflammatory state of the disease but might be an expression of the atherosclerotic process frequently observed in PsA.
引用
收藏
页码:1431 / 1436
页数:6
相关论文
共 43 条
  • [1] Ballara S, 2001, ARTHRITIS RHEUM, V44, P2055, DOI 10.1002/1529-0131(200109)44:9<2055::AID-ART355>3.0.CO
  • [2] 2-2
  • [3] Bevelacqua V, 2006, INT J MOL MED, V18, P415
  • [4] BREVIARIO F, 1992, J BIOL CHEM, V267, P22190
  • [5] Antiangiogenic effects of anti-tumor necrosis factor a therapy with infliximab in psoriatic arthritis
    Cañete, JD
    Pablos, JL
    Sanmartí, R
    Mallofré, C
    Marsal, S
    Maymó, J
    Gratacós, J
    Mezquita, J
    Mezquita, C
    Cid, MC
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (05): : 1636 - 1641
  • [6] Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis
    Chandran, Vinod
    Cook, Richard J.
    Edwin, Jonathan
    Shen, Hua
    Pellett, Fawnda J.
    Shanmugarajah, Sutharshini
    Rosen, Cheryl F.
    Gladman, Dafna D.
    [J]. RHEUMATOLOGY, 2010, 49 (07) : 1399 - 1405
  • [7] Chimenti MS, 2012, CLIN EXP RHEUMATOL, V30, P23
  • [8] Subclinical atherosclerosis in patients with psoriatic arthritis: a case-control study. Preliminary data
    Contessa, C.
    Ramonda, R.
    Lo Nigro, A.
    Modesti, V.
    Lorenzin, M.
    Puato, M.
    Zanon, M.
    Balbi, G.
    Doria, A.
    Punzi, L.
    [J]. REUMATISMO, 2009, 61 (04) : 298 - 305
  • [9] Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis
    Del Porto, F.
    Lagana, B.
    Lai, S.
    Nofroni, I.
    Tinti, F.
    Vitale, M.
    Podesta, E.
    Mitterhofer, A. P.
    D'Amelio, R.
    [J]. RHEUMATOLOGY, 2007, 46 (07) : 1111 - 1115
  • [10] High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies
    Drouart, M
    Saas, P
    Billot, M
    Cedoz, JP
    Tiberghien, P
    Wendling, D
    Toussirot, É
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2003, 132 (01) : 158 - 162